Sanofi(SNY) - 2021 Q3 - Quarterly Report

Exhibit 99.1 Sanofi announces positive Phase 1/2 study interim results for its first mRNA- based vaccine candidate PARIS – September 28, 2021 – Positive interim results from a Phase 1/2 study1 of Sanofi's mRNA-based COVID-19 vaccine candidate confirm the potential of recently-acquired Translate Bio's messenger RNA (mRNA) and lipid nanoparticle (LNP) platform and support Sanofi's mRNA strategy. The initial data from Phase 1/2 showed neutralizing antibody seroconversion (defined as 4-fold increase vs baseline ...